Dana Point, CA, United States of America

Sam L Nguyen

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent. Top assignees: Epizon Pharma, Inc., Epizon, Inc.. Active years: 2024-2026.

USPTO Granted Patents = 4 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.2

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Sam L Nguyen

Introduction

Sam L Nguyen is an accomplished inventor based in Dana Point, California. He has made significant contributions to the field of medical technology, particularly in the development of nanoparticle compositions for therapeutic applications. With a total of three patents to his name, Nguyen's work focuses on enhancing the efficacy of vitamin K2 in treatment methods.

Latest Patents

Nguyen's latest patents include "Nano-particles of menaquinone-9 and methods of treatment," which discloses compositions comprising nanoparticles of vitamin K2 and their methods of use. Another notable patent is "Nano-particles of menaquinone and methods of treatment," which also details compositions of nanoparticles of vitamin K2 and their applications in treatment.

Career Highlights

Throughout his career, Sam L Nguyen has worked with notable companies such as Epizon, Inc. and Epizon Pharma, Inc. His innovative approaches have positioned him as a key figure in the development of advanced medical treatments.

Collaborations

Nguyen has collaborated with esteemed professionals in his field, including John M Rudey and Eric Stephen Gruff. These partnerships have further enriched his research and development efforts.

Conclusion

Sam L Nguyen's contributions to the field of medical technology through his innovative patents and collaborations highlight his commitment to advancing healthcare solutions. His work continues to pave the way for new treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…